Alternative Thematic Report on implementation of the Convention on Elimination of all Forms of discrimination against Women on the issues related to women living with HIV from the affected groups (women – former prisoners, women using injected drugs, women sex workers).
Accessed: 04.10.2019
Downloaded from https://aidsinfo.nih.gov/guidelines on 10/19/2019
Recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America and the Pediatric Infectious Diseases Society
(This g...uideline was simultaneously published in The Pediatric Infectious Disease Journal on November 6, 2013.)
more
PLOS ONE | https://doi.org/10.1371/journal.pone.0193145 February 22, 2018 1 / 13
An analysis from the perspective of the health sector in Latin America and the Caribbean
Washington, D.C., 2017
In eastern and southern Africa
#EndAdolescentAIDS
July 2018
- A global call to action
- Case studies
- Blogs
- Next steps
PLOS ONE | https://doi.org/10.1371/journal.pone.0210937
February 5, 2019
A Summary
Accessed: 23.11.2019
Technical Brief
HIV patient monitoring and case surveillance
WHO/HIV/2017.11
October 2018
This publication was produced at the request of the United States Agency for International Development. It was prepared independently by David Lowe, David Hales, Britt Herstad, Billy Pick, Aisuluu Bolotbaeva, and Gulgun Jonboboeva.
Downloaded from https://aidsinfo.nih.gov/guidelines on 11/27/2019
Visit the AIDSinfo website to access the most up-to-date guideline.
Register for e-mail notification of guideline updates at https://aidsinfo.nih.gov/e-news.
Technical Update
HIV Treatment
July 2017
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...ted. Initially, due to their high prices, affordability of DAAs was limited in high-, middle- and low-
income countries alike. Now there is a divide between those countries where, because of intellectual
property barriers, prices have remained (very) high and other countries where generics are, or can be,
available at much lower prices. The result is a dual market
more
Tuberculosis cases, TB deaths